HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

Impact · against what's priced in

HUTCHMED gains a positive catalyst from expanded NRDL coverage for ELUNATE and the first-ever inclusion of TAZVERIK in China's Commercial Insurance Drug List, broadening its addressable market. Partners AstraZeneca, Eli Lilly, and Takeda see modest positive carry from these renewals and expanded indications, which secure near-term revenue stability in the Chinese market.

HCM+0.70

No priced-in read yet